• Savara highlighted a November 22, 2026, PDUFA date for MOLBREEVI, its investigational inhaled treatment for autoimmune pulmonary alveolar proteinosis.
• IMPALA-2 met its primary endpoint, with a 6-percentage-point lung diffusion capacity advantage over placebo at week 24 (p=0.0007).
• The lung diffusion capacity advantage reached 6.9 percentage points at week 48 (p=0.0008).
• Respiratory quality-of-life scores improved versus placebo at week 24 (p=0.0072); the week-48 difference was not statistically significant.
• Treatment discontinuations were 3%, with none attributed to drug-related adverse events.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Savara Inc. published the original content used to generate this news brief on November 09, 2026, and is solely responsible for the information contained therein.